[go: up one dir, main page]

AU2001269314A1 - Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds - Google Patents

Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds

Info

Publication number
AU2001269314A1
AU2001269314A1 AU2001269314A AU6931401A AU2001269314A1 AU 2001269314 A1 AU2001269314 A1 AU 2001269314A1 AU 2001269314 A AU2001269314 A AU 2001269314A AU 6931401 A AU6931401 A AU 6931401A AU 2001269314 A1 AU2001269314 A1 AU 2001269314A1
Authority
AU
Australia
Prior art keywords
therapeutic
pharmaceutical compounds
prophylactic use
reduced forms
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269314A
Inventor
Anthony Aktinson
Andrew Marc Salomon
Ernest Wulfert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Fleming Ltd
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of AU2001269314A1 publication Critical patent/AU2001269314A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001269314A 2000-07-11 2001-07-10 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds Abandoned AU2001269314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0017060.5 2000-07-11
GBGB0017060.5A GB0017060D0 (en) 2000-07-11 2000-07-11 Production, stabilisation and use of reduced forms of pharmaceutical compounds
PCT/GB2001/003081 WO2002003972A2 (en) 2000-07-11 2001-07-10 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds

Publications (1)

Publication Number Publication Date
AU2001269314A1 true AU2001269314A1 (en) 2002-01-21

Family

ID=9895475

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001270778A Abandoned AU2001270778A1 (en) 2000-07-11 2001-07-10 Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001269314A Abandoned AU2001269314A1 (en) 2000-07-11 2001-07-10 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001270778A Abandoned AU2001270778A1 (en) 2000-07-11 2001-07-10 Production, stabilisation and use of reduced forms of pharmaceutical compounds

Country Status (6)

Country Link
US (2) US20030181389A1 (en)
EP (2) EP1301181A2 (en)
JP (2) JP2004502728A (en)
AU (2) AU2001270778A1 (en)
GB (1) GB0017060D0 (en)
WO (2) WO2002003972A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
ATE442143T1 (en) 2001-03-21 2009-09-15 Eisai R&D Man Co Ltd REDUCED DRUGS CONTAINING VITAMIN B2
JP3742602B2 (en) * 2001-05-09 2006-02-08 株式会社カネカ Stable solution of reduced coenzyme Q
JP4684553B2 (en) * 2001-09-27 2011-05-18 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア Regulation of physiological processes and drugs useful for this
JP3822479B2 (en) * 2001-10-10 2006-09-20 株式会社カネカ Stabilized composition of reduced coenzyme Q aqueous solution
US20060211748A1 (en) * 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
US20080200563A1 (en) * 2004-07-22 2008-08-21 Thiomatrix Forschungs- Und Beratungs- Gmbh Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
TW200722076A (en) * 2005-03-29 2007-06-16 Kaneka Corp Composition for increasing anti-oxidation activity in blood
SI2004155T1 (en) 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
CN104529939B (en) 2006-03-29 2019-05-07 维斯塔实验室有限公司 3,7-Diamino-10H-phenothiazine compound salt and use thereof
US7915432B2 (en) * 2006-12-12 2011-03-29 Cytyc Corporation Method for improving the shelf-life of hematoxylin staining solutions
ES2739546T3 (en) * 2007-06-19 2020-01-31 Wista Lab Ltd Phenothiazine compounds to treat mild cognitive impairment
SI2205245T1 (en) * 2007-10-03 2015-10-30 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
CN101655449A (en) * 2008-08-20 2010-02-24 鸿富锦精密工业（深圳）有限公司 Device for measuring catalytic performance of photocatalyst
US8796448B1 (en) * 2010-12-09 2014-08-05 Prosetta Antiviral Inc. Compounds, compositions, and methods for treating Alzheimer's disease
US20140148446A1 (en) * 2010-09-23 2014-05-29 University Of North Texas Health Science Center Compounds that enable alternative mitochondrial electron transfer
WO2012107706A1 (en) 2011-02-11 2012-08-16 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
JP6370674B2 (en) * 2014-10-22 2018-08-08 国立研究開発法人国立長寿医療研究センター Tauopathy drug and screening method thereof
US11413240B2 (en) * 2016-12-29 2022-08-16 Board Of Regents, The University Of Texas System Methylene blue solution for the treatment of oral lesions
JP2018070581A (en) * 2017-04-19 2018-05-10 誠一 荒木 Reduced-vitamin b2 formulation
JP2023524146A (en) * 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド Methylthioninium compounds used to treat hypoxemia
GB202204185D0 (en) * 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4711894A (en) * 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9323399D0 (en) * 1993-11-12 1994-01-05 Univ Newcastle Ventures Ltd Pharmaceutical formulations
EP0778773A1 (en) * 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache

Also Published As

Publication number Publication date
WO2002004025A1 (en) 2002-01-17
AU2001270778A1 (en) 2002-01-21
EP1299125A1 (en) 2003-04-09
US20030181389A1 (en) 2003-09-25
JP2004502728A (en) 2004-01-29
JP2004502743A (en) 2004-01-29
US20040033936A1 (en) 2004-02-19
EP1301181A2 (en) 2003-04-16
GB0017060D0 (en) 2000-08-30
WO2002003972A2 (en) 2002-01-17
WO2002003972A3 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2001280440A1 (en) Treatment of human herpesviruses using hyperthermia
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2002354476A1 (en) Pyrazolopyridine derivatives and medicinal use thereof
AU2002231206A1 (en) Treatment of depression
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2001297611A1 (en) Pharmaceutical uses and synthesis of diketopiperazines
AU2002230781A1 (en) Pharmaceutical uses and synthesis of benzobicyclooctanes
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001245414A1 (en) Treatment of allergies
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU2002212327A1 (en) Pharmaceutical preparation comprised of milk-thistle and terpenes
AU2001268236A1 (en) Use of aicar and related compounds
AU2001281950A1 (en) Regulation of human thimet oligopeptidase-like enzyme
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis